HC Wainwright Cuts EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $22.00

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target cut by HC Wainwright from $30.00 to $22.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ FY2024 earnings at ($2.15) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

Several other research analysts have also commented on the stock. Robert W. Baird cut their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday. Chardan Capital upped their price target on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Scotiabank initiated coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price objective for the company. Jefferies Financial Group started coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

EyePoint Pharmaceuticals Price Performance

EyePoint Pharmaceuticals stock opened at $10.49 on Monday. EyePoint Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $30.99. The stock has a market capitalization of $561.42 million, a P/E ratio of -5.25 and a beta of 1.50. The firm’s 50-day moving average is $9.71 and its two-hundred day moving average is $9.91.

Institutional Trading of EyePoint Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. lifted its stake in shares of EyePoint Pharmaceuticals by 44.0% in the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock valued at $77,000 after buying an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after acquiring an additional 4,172 shares during the period. Greenwich Wealth Management LLC grew its holdings in shares of EyePoint Pharmaceuticals by 8.3% during the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after purchasing an additional 900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of EyePoint Pharmaceuticals by 271.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after purchasing an additional 7,953 shares during the period. Finally, Cyndeo Wealth Partners LLC acquired a new position in shares of EyePoint Pharmaceuticals in the third quarter valued at $100,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.